Updated results and longer follow-up from the AUGMENT-101 phase 2 study of revumenib in all patients with relapsed or refractory (R/R) KMT2Ar acute leukemia Meeting Abstract

  


Authors: Aldoss, I.; Issa, G. C.; Blachly, J. S.; Thirman, M. J.; Mannis, G. N.; Arellano, M. L.; DiPersio, J. F.; Traer, E.; Zwaan, C. M.; Shukla, N.; Cuglievan, B.; Grove, C. S.; Greenwood, M.; McMahon, C. M.; Perl, A. E.; Stone, R. M.; Papayannidis, C.; Dickens, D. S.; Heiblig, M.; Žučenka, A.; Montesinos, P.; Mantzaris, I.; Kovacsovics, T.; Shami, P. J.; Yu, L.; Bagley, R. G.; McNeer, N.; Stein, E. M.
Abstract Title: Updated results and longer follow-up from the AUGMENT-101 phase 2 study of revumenib in all patients with relapsed or refractory (R/R) KMT2Ar acute leukemia
Meeting Title: 66th Annual Meeting of the American Society of Hematology (ASH)
Journal Title: Blood
Volume: 144
Issue: Suppl. 1
Meeting Dates: 2024 Dec 7-10
Meeting Location: San Deigo, CA
ISSN: 0006-4971
Publisher: American Society of Hematology  
Date Published: 2024-11-05
Start Page: 211
End Page: 214
Language: English
ACCESSION: WOS:001414317000011
DOI: 10.1182/blood-2024-194384
PROVIDER: wos
Notes: Meeting Abstract -- Source: Wos
Altmetric
What is Altmetric?
Citation Impact
What is Dimensions Citation Badge?
BMJ Impact Analytics
MSK Authors
  1. Eytan Moshe Stein
    342 Stein
  2. Neerav Shukla
    159 Shukla
Related MSK Work